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A B S T R A C T
The poor prognosis of cholangiocarcinoma (CCA) is in part due to late diagnosis, which is currently achieved by
a combination of clinical, radiological and histological approaches. Available biomarkers determined in serum
and biopsy samples to assist in CCA diagnosis are not sufficiently sensitive and specific. Therefore, the identi-
fication of new biomarkers, preferably those obtained by minimally invasive methods, such as liquid biopsy, is
important. The development of innovative technologies has permitted to identify a significant number of genetic,
epigenetic, proteomic and metabolomic CCA features with potential clinical usefulness in early diagnosis,
prognosis or prediction of treatment response. Potential new candidates must be rigorously evaluated prior to
entering routine clinical application. Unfortunately, to date, no such biomarker has achieved validation for these
purposes. This review is an up-to-date of currently used biomarkers and the candidates with promising char-
acteristics that could be included in the clinical practice in the next future. This article is part of a Special Issue
entitled: Cholangiocytes in Health and Disease edited by Jesus Banales, Marco Marzioni, Nicholas LaRusso and
Peter Jansen.
1. Introduction
After hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA) is
the second most common primary tumor of the liver, accounting for
approximately 15% of all primary liver cancers [1] and 2% of cancer-
related deaths worldwide per year. The term CCA refers to a hetero-
geneous group of malignancies affecting the biliary epithelium that are
classified into three entities depending on the anatomical location: i)
intrahepatic CCA (iCCA), arising from the small bile ducts within the
liver, and two types of extrahepatic CCAs, both arising from the ductal
epithelium of the extrahepatic biliary tree; ii) distal CCA (dCCA) and iii)
perihilar CCA (pCCA). Several other classifications have been proposed
based on additional aspects of these tumors [2].
The silent evolution of the disease and the fact that its clinical
manifestations are nonspecific and mainly related to the biliary ob-
struction caused by the tumor [3] justify the late diagnosis of patients
with CCA, when the tumor is already at an advanced stage. These cir-
cumstances partly accounts for the poor prognosis and the high mor-
tality rate of these patients. The overall 5-year survival after resection is
usually lower than 40%, while in non-operable CCAs the overall 5-year
survival is less than 5%. Diagnosis of CCA is based on a combination of
clinical, radiological, biochemical and histological approaches, but
none of the currently available biomarkers determined in fluids or in
biopsy samples to assist in the diagnosis of this disease are sufficiently
sensitive and specific. Extensive research is being carried out to identify
biomarkers that can contribute to a better understanding of the
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molecular basis of the disease, as well as to assist in the diagnosis and
prognosis of CCA.
2. Clinical usefulness and limitations of available biomarkers in
patients with CCA
The usefulness of tumor biomarkers lies in their ability to provide an
early diagnosis of the disease, to establish individual prognosis and risk
of relapse, or to help in the choice of the best treatment option (sur-
gical, locoregional or systemic). The ideal biomarker for the diagnosis
of CCA, as for any other cancer, should be simple and affordable
(widely available), highly sensitive (to detect the disease at an early
stage, preferably when curative therapy can be provided), and specific
(to distinguish CCA from other malignant or benign diseases).
Unfortunately, for CCA, this type of biomarker has yet not been iden-
tified.
At present, the carcinoembryonic antigen (CEA) and the carbohy-
drate antigens 19-9 (CA 19-9) and 125 (CA 125) are used clinically as
serum markers for CCA, but they have low sensitivity and specificity
and are not adequate for early detection. For diagnostic purposes,
serum CA 19-9 is neither highly sensitive nor specific, as moderately
elevated le-vels of this biomarker can be observed in situations of be-
nign bile duct obstruction. Thus, the sensitivity and specificity of CA 19-
9 for iCCA are 62% and 63%, respectively.
Other serum biomarkers, such as cytokeratin-19 fragment (CYFRA
21-1) and CA-242, have been reported to have higher specificity than
CA 19-9 for iCCA in a limited number of studies [4], but are not in
routine clinical use. Despite important efforts in past years to identify
novel and more specific and sensitive markers for CCA, not only in
serum (mucin 5AC, trypsinogen, interleukin 6, platelet-lymphocyte
ratio, progranulin, etc.), but also in bile (insulin-like growth factor type
1, lipocalin-2, microRNA-laden vesicles, pancreatic elastase/amylase
ratio, proteomic profile, etc) and urine (volatile organic compounds,
proteomic profiles), none of the candidates evaluated have been con-
sidered suitable for clinical use [5].
Diagnosis of CCA usually relies on a combination of imaging tech-
niques, including ultrasonography, computed tomography (CT), posi-
tron emission tomography (PET), magnetic resonance imaging (MRI),
or advanced endoscopic biliary imaging techniques (Spyglass
Spyscope). Approaches based on brush cytology can be truly challen-
ging in the presence of chronic damage of the biliary tract, even when
using molecular techniques to identify genetic and molecular altera-
tions by means of fluorescence in-situ hybridization (FISH).
Immunostaining to detect markers of HCC (e.g., GPC3, HSP70, and
glutamine synthetase) or progenitor cell features (e.g., K19, EpCAM) is
recommended to distinguish iCCA from mixed HCC-CCA tumors if this
information can influence patient management [6].
The first step to evaluate the usefulness of any novel biomarker in
the early diagnosis of CCA is to establish which high-risk population
should be screened. The two groups with the highest risk of developing
CCA are patients with primary sclerosing cholangitis (PSC) and patients
with choledocal cysts. Population-based studies suggest that the annual
risk for CCA in PSC patients is approximately 2% with a 10- and 30-year
cumulative incidence of 6–11% and 20%, respectively [7]. For this
reason, performing liver function tests every 3-6 months and an annual
MRI and CA 19-9 analysis is usually recommended among young adults
over the age of 20 with large duct PSC, although no formal prospective
validation of this follow-up strategy has ever been attempted. Bio-
markers are likely more useful among individuals with suspicious
imaging features (a new dominant stricture or the development of focal
bile duct thickening, irregularity or enhancement), symptoms that
suggest biliary obstruction or laboratory tests that worsen over time. In
these situations, elevated levels of CA 19-9, greater than 100 IU/ml in
the absence of cholangitis, are highly suggestive of CCA. Among pa-
tients with choledocal cysts, the risk of CCA varies from 2.5% to 26%
[8]. This risk increases notably in patients older than 20 years of age,
and it is considered a clear risk factor when symptom onset occurs in
patients older than 60. However, in Western countries most CCAs, and
particularly iCCA, are diagnosed in the absence of any known risk
factor, which makes screening strategies unfeasible.
Once the diagnosis of CCA has been established, a relevant question
that biomarkers could help responding is whether the tumors should be
resected or not. Currently, there are three commonly used pCCA clas-
sification systems: i) the Bismuth-Corlette classification, ii) the
Memorial Sloan-Kettering Cancer Center staging system, and iii) the
American Joint Committee on Cancer/Union for International Cancer
Control (AJCC/UICC) system. None of these systems are perfect and
none can be used to predict the survival time of patients with un-
resectable disease. The AJCC/UICC 7th tumor-node-metastasis (TNM)
staging system is the most widely used. Several immunohistochemical
markers are associated with worse outcomes after resection, including
LIM and SH3 protein 1, suppressor of cytokine signaling 3, interleukin-
8, matrix metalloproteinase-9, or CD15 expression. Among the serum
biomarkers, high levels of CA 19-9 or GGT are usually associated with
larger tumor size, lymph node metastasis or vascular invasion. Patients
with unresectable CCA typically have higher CA 19-9 levels than pa-
tients with resectable tumors. Some studies have reported that pre-
operative CA 19-9 levels> 100 U/ml are associated with worse re-
currence-free survival post-resection [9]. However, there is no cutoff
value that can be used to contraindicate surgery. As mentioned, bile
duct obstruction or acute cholangitis may increase CA 19-9 levels. Ac-
cordingly, in the case of bile duct obstruction, CA 19-9 levels should be
reassessed after biliary drainage, taking into account that the half-life of
CA 19-9 is up to three days.
Another important aspect in the usefulness of biomarkers is their
ability to discriminate between HCC and iCCA. Serum levels of CA 19-9,
sialic acid, and CA 242 tend to be higher in CCA, while alpha-feto-
protein and glypican-3 tend to be higher in HCC; however, there is no
combination of biomarkers that specifically distinguishes both tumors
[10,11]. In addition, it must be taken into account that tumors with
mixed differentiation are not unusual. A recent study has described the
usefulness of tumor-associated microparticles in serum for diagnosis of
liver tumors. In particular, higher serum concentration of micro-
particles positive for AnnexinV, EpCAM and ASGPR1 were found in
patients with liver tumors (i.e., HCC or CCA) compared to patients with
cirrhosis [12]. Differential diagnosis by histology of iCCA vs HCC or
metastasis remains a challenge and no specific markers have been va-
lidated. A panel of immunohistochemistry markers (hepatocyte-specific
antigen, MOC-31, pCEA, CD10, and CD34) permits to exclude metas-
tasis, and the cytokeratin profile (CK7+, CK19+, CK20-) in combi-
nation with the hepatocytic marker HepPar1- permits to exclude HCC
[2].
Since no targeted therapy with proved effectiveness against CCA is
yet available, the use of biomarkers to customize CCA chemotherapy/
immunotherapy makes less sense. However, several agents currently
being used in clinical trials with patients with CCA have specific targets
expressed in these tumors.
High-throughput, large-scale analytical methods to quantify gene
expression, proteins and metabolites in tissue, blood, bile and urine are
now available (Fig. 1). The so-called “omics” technologies aim to
identify biomarkers that permit to understand tumor biology and use
this information to identify novel targets for future therapeutic strate-
gies, define different clinical entities and pathological processes and
estimate the severity of the disease and predict long-term outcome for
patients. “Omics” approaches include genomics for DNA variations,
transcriptomics for all RNA molecules - including messenger RNA
(mRNA), ribosomal RNA (rRNA), and other noncoding RNA such as
microRNAs (miRNA) -, proteomics for peptides and proteins and me-
tabolomics for intermediate products of metabolism. It has been de-
monstrated that some chromosomal abnormalities and specific mole-
cular prognostic markers can be used as tools for the stratification of
patients into risk groups. Epigenetic analysis refers to heritable
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modifications of the genome that do not affect the DNA sequence but
directly affect the pattern of gene expression. These include DNA me-
thylation, histone post-translational modifications, chromatin re-
modeling and non-coding RNAs (miRNAs). These changes to the
genome may be reversible and it has been shown that they affect the
epigenome and contribute to the pathogenesis of different diseases,
including cancer.
Proteomic analyses complement DNA- and RNA-based studies, as
there is a close correlation between the proteome or changes in protein
glycosylation and the biological activity of the cell or system. Proteins
are directly responsible for different functions in the cell, thus abnormal
protein expression or an altered pattern of proteins can be an indication
of a pathological condition. The identification of a protein expression
profiling in CCA could be a valuable diagnostic and prognostic tool,
where a particular protein signature is expressed in a distinct pattern
that can be tied to a specific clinical feature or can be used for a dif-
ferential diagnosis between CCA and HCC. The analysis of the whole
metabolome, or molecules with low molecular weight present in a
biological compartment (tissue or biological fluid), which are the result
of multiple enzymatic reactions, can provide useful information on the
biochemical activity and physiological state of an organism. Of note,
the use of appropriate statistical analysis and bioinformatics tools is
necessary for handling big and complex data volumes. Last but not
least, circulating tumor cells (CTCs) are cells that reach the bloodstream
from a primary tumor and may be responsible of subsequent growth of
additional tumors in distant organs (metastasis) (Fig. 1). They have
been detected in various metastatic carcinomas such as breast, lung,
and colorectal cancer, but are extremely rare in healthy subjects and
patients with nonmalignant diseases.
The search for biomarkers using “omics” technologies has permitted
to identify alterations in cellular signaling pathways and biochemical
processes, providing an insight into the mechanisms that underlie tu-
morigenesis. Some proteins currently under investigation as potential
either biomarkers or targets for cancer therapy are signaling proteins
involved in cell proliferation, motility, or survival pathways, as well as
mutated enzymes responsible for the appearance or increased levels of
rare metabolites.
It is important to highlight that pre-clinical studies, carried out in
cultured cells and animal CCA models, complement the results obtained
in clinical setting and the combined used of both can help to increase
our understanding of CCA biology. This has been useful, for instance to
assess the role in CCA development and progression of altered expres-
sion of genes or dysregulated signaling pathways.
In the next sections of the present review, new advances in research
fields related to the investigation of novel diagnostic and prognostic
biomarkers in CCA will be described in detail. More detailed informa-
tion regarding targeted and individualized therapeutic approaches to
hepatobiliary neoplasia can be found in other chapters of this special
issue.
3. Use of OMICs approaches in search of novel biomarkers for CCA
3.1. Genomic features
Several studies have pointed out the genomic heterogeneity and the
most prevalent genomic alterations present in CCAs (Fig. 2). These may
affect DNA repair (TP53) [13–17], growth pathways (KRAS, BRAF,
SMAD4, FGFR2, PTPN3) [13,16–22], chromatin-remodeling (KMT2C,
ARID1A, PBRM1 and BAP1) [14–19] and developmental pathways,
such as the Notch and Wnt signaling pathways, which play important
roles in the growth of these cancers [23–25]. The FGFR2 fusion genes
are of special interest, as they are not detected in other liver malig-
nancies and are pharmacologically targetable and have diagnostic value
[17,18,20,26,27]. Other mutations in IDH1 and IDH2 alter the methy-
lation status of CCA cells [15,17–19,28,29]. The genomic variability of
CCAs may be the reflection of different etiologies and risk factors and/
or the result of the biological selection of the mutations that allow the
tumor to grow [15,19,21,24,26]. These genomic mutations result in the
expression of different molecular profiles that may allow the stratifi-
cation of CCAs and a more precise therapeutic strategy. Furthermore, a
recent study has demonstrated that targeted therapies may show ben-
eficial effects when CCAs are genetically selected [18].
3.2. Epigenetic features
Little is still known about the epigenetic modifications affecting
CCAs (Fig. 2). Mutations in IDH genes are known to produce a genome-
wide DNA hypermethylation that may change the expression pattern of
Fig. 1. Circulating biomarkers in cholangiocarcinoma.
Different types of biomarkers can be analyzed in peripheral
circulation: circulating tumor cells (CTCs) escaping from
primary sites, extracellular vesicles (EV) containing nucleic
acids and proteins, cell-free DNA and RNA released from
tumor cells, and proteins and metabolites secreted by tumor
cells.
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several genes [30]. Epigenetic alterations, similarly to genetic muta-
tions, affect important pathways involved in the onset of the disease.
Some examples include: i) HNF4α silencing, which blocks hepatocyte
differentiation, promoting biliary tract cancers [29]; ii) signaling
pathways such as Wnt/β-catenin, transforming growth factor beta (T-
GFβ) and PI3K signaling [31]; iii) HOX genes [32]; and iv) histone
deacetylase 6 (HDAC6) overexpression, which causes cholangiocyte
primary cilium shortening and promotes cell growth [33]. Epigenetic
alterations may also be important for diagnostic and prognostic pur-
poses. CCAs exhibit altered DNA methylation and hidroxymethylation
patterns [34]. Interestingly, a DNA methylation gene biomarker profile
from cells of biliary brushes has been postulated as being highly sen-
sitive and specific for CCA diagnosis [35]. Moreover, the expression of
histone deacetylases, such as HDAC1, may have prognostic value in
CCAs [36].
3.3. Transcriptomic biomarkers
Genetic and epigenetic modifications finally result in transcriptomic
changes that encompass the different RNA species (mRNAs, miRNAs
and other non-coding RNAs). Several studies have shown that CCAs
present particular signatures of gene expression when compared with
both non-tumor liver tissue and HCC [37–39]. Thus, two different types
of iCCA have been described according to their gene expression pat-
terns: the “inflammation class”, characterized by the activation of in-
flammatory signaling pathways, and the “proliferation class”, related to
the activation of classical oncogenic pathways, which is associated with
a worse outcome [21].
In the last decade, an increasing number of studies have highlighted
the implication of different microRNAs in the pathogenesis of CCA, as
well as their potential value for diagnosis and prognosis (Table 1)
[40,41]. Thus, deregulated microRNA expression has been linked to
different molecular aspects of cholangiocarcinogenesis, such as pro-
liferation, invasion and migration, epithelial to mesenchymal transition
(EMT), epigenetic modifications, chemoresistance and/or apoptosis
evasion [42]. In this regard, abnormal microRNA profiles in CCA tumor
samples and cell lines have been reported (Table 1). Particularly, miR-
21 overexpression in CCA tissue specimens, regardless of its etiology,
seems to be a potential candidate biomarker, with 95% sensitivity and
100% specificity in discriminating between CCA and normal tissues
[43,44]. Tissue miR-21 expression significantly correlates with the
clinical stage at diagnosis and the differentiation status, and high miR-
21 expression in iCCA tissues is associated with poor overall and pro-
gression-free survival [45,46]. Likewise, miR-21 expression is highly
upregulated in CCA cell lines compared with nonmalignant cho-
langiocytes [47]. Experimental inhibition of miR-21 significantly
reduces cell proliferation, anchorage-independent growth and invasion
in vitro as well as tumor growth in vivo [46,48]. MiR-21 target genes
include tumor suppressor-genes such as phosphatase and tensin
homolog (PTEN) and protein tyrosine phosphatase non-receptor type 14
(PTPN14), tissue inhibitor of metalloproteinase-3 (TIMP-3), PDCD4,
and RECK, among others [43–48]. MicroRNA signatures in tissue
samples could also provide insight into the different histological grades
and clinical subtypes of iCCA. A recent study, for instance, proposes a
specific panel of miRNAs linked to the different subtypes of iCCA in-
duced by O. viverrini infection [49]. MicroRNA profiling in tissue spe-
cimens can also serve to specifically differentiate tumors with similar
clinical presentations such as CCA and pancreatic adenocarcinoma
[50]. One interesting feature of miRNAs as biomarkers is their presence
and stability in biofluids, which enables non-invasive approaches for
CCA diagnosis. In this regard, some of the previous results obtained in
tissue specimens are consistent with determinations carried out in
plasma and serum samples. Thus, circulating levels of miR-21 have
shown a high capacity to discriminate between patients with iCCA and
healthy controls, with an 87.8% sensitivity and 90.5% specificity when
determined in serum and with an area under the receiver operating
characteristic curve (AUC) of 0.9081 in serum and 0.94 in plasma
[46,51]. Similarly, the expression of miR-26a not only is increased in
CCA tissues and cell lines promoting CCA growth, but also is elevated in
serum of CCA patients with 84.8% sensitivity and 81.8% specificity in
distinguishing CCA from healthy controls and an AUC value of 0.899
[52,53]. Interestingly, miR-26a expression could also serve as a po-
tential prognostic tool in CCA, since its levels significantly correlate
with TNM stage and specifically fall down after potentially curative
surgeries [53]. The expression of other miRNAs such as miR-106a is
downregulated in serum of CCA and may function as a predictor of poor
prognosis [54]. Although miR-150 expression levels are significantly
lower in iCCA compared with healthy tissue, the levels of this miRNA
are elevated in plasma of iCCA patients, with a sensitivity and specifi-
city of 80.6% and 58.1%, respectively. Furthermore, the use of miR-150
in combination with CA 19-9 further improves the power of screening
iCCA [55]. Concerning liver fluke-associated iCCA, serum miR-192 was
reported as an interesting candidate for O. viverrini-related CCA diag-
nosis (with 74% sensitivity and 72% specificity and 0.803 AUC value),
and high serum levels of this miRNA correlated with shorter survival
and lymph-node metastasis [56]. Of note, urinary miR-192 and miR-21
levels are also potential biomarkers for CCA, and their combined levels
hold stronger diagnostic power differentiating CCA patients from
healthy subjects than a single miRNA [57]. Moreover, the analysis of
iCCA and controls tissue samples permitted the identification of miRNA
profiles associated with increasing histological differentiation. Also
seven miRNAs (miR-16-2, miR-320a, miR-193a, miR-378a, miR-320b,
Fig. 2. Most frequent genomic and epigenetic alterations with
potential interest in diagnosis of cholangiocarcinoma. Relevant
references are indicated in square brackets.
ARID1A, AT-rich interaction domain 1A; BAP1, BRCA1-asso-
ciated protein 1; CTNNB1, catenin beta 1; FGFR2, fibroblast
growth factor receptor 2; HDAC6, histone deacetylase 6; IDH1/2,
isocitrate dehydrogenase 1 and 2; KMT2C, lysine methyl-
transferase 2C; PI3K, phosphatidylinositol 3-kinase; PBRM1,
polybromo 1; PTPN3, protein tyrosine phosphatase non-receptor
type 3; TGFβ, transforming growth factor beta. Other tumor
suppressor genes and oncogenes: TP53, KRAS, BRAF, SMAD4.
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miR-505 and miR-483) were found dysregulated in matched plasma of
these patients [58]. In addition to these examples regarding plasma,
serum and urine, owing to its direct contact with the tumor, bile seems
to be also a suitable biofluid for miRNA-based CCA diagnosis. High-
throughput PCR-based miRNA expression profiling performed in bile
samples revealed miR-9 as a candidate for CCA diagnosis (with 88.9%
sensitivity and 100% specificity and an AUC of 0.975). Moreover, miR-
145* could also be considered another potential candidate (with 77.8%
sensitivity and 100% specificity and an AUC of 0.975) [59]. Given that
CCA has a poor prognosis, diagnosis at an early stage, when the disease
is still amenable to cure, is crucial. Since PSC is a well-established risk
factor for CCA development, various studies have analyzed the miRNA
profile in bile and serum of patients with PSC and/or CCA [60,61]. One
of these studies identified a significant difference in serum miR-222 and
miR-483-5p in CCA compared with PSC [61], and in another study, the
expression of a panel of 5 miRNAs (miR-1281, miR-126, miR-26a, miR-
30b and miR-122) was significantly different between patients with
CCA vs PSC [60]. In bile, miR-412, miR-640, miR-1537 and miR-3189
were identified as differentially expressed when comparing patients
with PSC and PSC/CCA [60].
Recently, to assess the overall diagnostic value of miRNAs as bio-
markers for CCA, some meta-analyses have been carried out recently
[62,63]. The pooled analysis of the available data after carrying out a
systematic literature search has demonstrated that miRNAs are pro-
mising tools for the diagnosis of CCA patients. Two independent meta-
analyses have shown a pooled sensitivity of 0.83 and 0.75, and speci-
ficity of 0.79 and 0.914 and a pooled AUC of 0.88 and 0.90 [62,63].
Regarding the specimen types, bile exhibited the highest diagnostic
efficiency (AUC value of 0.9572), followed by serum (0.9132), tissue
(0.8465) and urine (0.7448) [62].
Finally, extracellular vesicles (EVs) are attracting great interest as
potential containers of biomarkers for diseases (Fig. 1). Recently, mi-
croRNAs contained in bile-extracted extracellular vesicle have been
postulated as an option for CCA diagnosis [64]. Here, a novel bile-based
5-miRNA panel and a mathematical model with a sensitivity and spe-
cificity of 67% and 96%, respectively, were suggested. However, fur-
ther studies are needed to validate these data as well as to evaluate the
miRNA profile of serum and urine EVs from CCA patients.
3.4. Proteomic biomarkers
Mass spectrometry (MS) technology allows the massive identifica-
tion and relative quantification of proteins present in different biolo-
gical samples [65]. With the clinical demand of minimal or non-in-
vasive biomarkers, MS-based proteomics has become a useful tool for
the analysis of different biofluids to find accurate and specific proteins
biomarkers for diagnosis, prognosis, patient stratification or response to
therapy [66]. Several proteomic studies have identified potential di-
agnostic biomarkers in bile and urine with a better diagnostic value
than the general non-specific tumor markers used in serum. A specific
peptide pattern accurately discriminated between benign and malig-
nant biliary diseases, showing 78% specificity, 84% sensitivity and an
AUC of 0.87 in CCA patients compared to patients with cholangitis
[67]. Additionally, the SSP411 protein has been identified as a pro-
mising potential bile biomarker for CCA diagnosis, with 85.7% of sen-
sitivity and 76.9% of specificity and 0.836 AUC for CCA patients
compared with patients with PSC [68]. However, since invasive pro-
cedures are needed for the collection of bile samples, urine-based
proteomics has been proposed as a feasible alternative to overcome this
limitation. A peptide marker panel in the urine of patients with CCA,
PSC or benign biliary disorder showed high diagnostic potential for
CCA in comparison to PSC and benign biliary disorder with 83% sen-
sitivity, 73% specificity and AUC of 0.87 [69]. Serum is also another
accessible biofluid that requires a non-invasive method of collection.
However, MS proteomics are hard to implement in these samples due to
the high abundance of some proteins, such as albumin or
Table 1
Diagnostic value of miRNAs as biomarkers in CCA.
Name Change in CCA Clinical sample Sensitivity (%) Specificity (%) AUC value Reference
miR-21 CCA vs normal tissue Tissue 95 100 0.995 [42]
miR-21 CCA vs normal tissue Tissue 95 100 0.995 [43]
miR-21 Upregulation iCCA vs Healthy Controls Serum 87.8 90.5 0.908 [45]
miR-21 Upregulation iCCA vs Healthy Controls Plasma – – 0.94 [50]
miR-26a Upregulation CCA vs Healthy Controls Serum 84.8 81.8 0.899 [52]
miR-106a Downregulation CCA vs Healthy Serum 81.6 85 0.89 [53]
miR-150 Upregulation iCCA vs Healthy Controls Plasma 80.6 58.1 0.764 [54]
miR-192 Upregulation O. viverrini CCA vs Healthy Controls Serum 74 72 0.803 [55]
miR-9 Upregulation CCA/GBC vs choledocholitiasis Bile 88.9 100 0.975 [58]
miR-145 Upregulation CCA/GBC vs choledocholitiasis Bile 77.8 100 0.975 [58]
miR-105 Upregulation CCA/GBC vs choledocholitiasis Bile 77.8 100 – [58]
miR-147b Upregulation CCA/GBC vs choledocholitiasis Bile 66.7 100 – [58]
miR-302 Upregulation CCA/GBC vs choledocholitiasis Bile 88.9 100 – [58]
miR-199-3p Upregulation CCA/GBC vs choledocholitiasis Bile 88.9 100 – [58]
miR-222 Upregulation CCA/GBC vs choledocholitiasis Bile 88.9 100 – [58]
miR-942 Upregulation CCA/GBC vs choledocholitiasis Bile 77.8 100 – [58]
miR-26a Downregulation CCA vs PSC Serum 52 93 0.78 [59]
miR-30b Downregulation CCA vs PSC Serum 52 88 0.78 [59]
miR-122 Downregulation CCA vs PSC Serum 32 90 0.65 [59]
miR-126 Downregulation CCA vs PSC Serum 68 93 0.87 [59]
miR-1281 Downregulation CCA vs PSC Serum 55 90 0.83 [59]
miR-222 Upregulation CCA vs PSC Serum – – 0.71 [60]
miR-483-5p Upregulation CCA vs PSC Serum – – 0.70 [60]
miR-412 Upregulation PSC/CCA vs PSC Bile 50 89 0.81 [59]
miR-640 Upregulation PSC/CCA vs PSC Bile 50 92 0.81 [59]
miR-1537 Upregulation PSC/CCA vs PSC Bile 67 90 0.78 [59]
miR-3189 Upregulation PSC/CCA vs PSC Bile 67 89 0.8 [59]
miR-21 Upregulation O. viverrini CCA vs Healthy Controls Urine 63.6 71.4 0.682 [56]
miR-192 Upregulation O. viverrini CCA vs Healthy Controls Urine 63.6 66.7 0.682 [56]
miR-21, miR-192 Upregulation O. viverrini CCA vs Healthy Controls Urine 81.8 71.4 0.849 [56]
miR-191, 486-3p, 1274b, 16, 484 CCA vs Control group EV in Bile 67 96 – [63]
AUC, area under the receiver operating characteristic curve; CCA, cholangiocarcinoma; EV, extracellular vesicles; GBC, gallbladder carcinoma; PSC, primary sclerosing cholangitis.
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immunoglobulins, which present a high dynamic range, making the
identification of less abundant proteins difficult [65,67]. Advances in
the MS technology or new methodologies for serum protein fractiona-
tion would be necessary for biomarker discovery in this fluid.
Regarding EVs, a recent study has described differentially expressed
proteins in serum EVs of CCA, PSC, HCC or healthy individuals. Several
of these proteins showed high sensitivity and specificity for the differ-
ential diagnosis and have been suggested as novel potential biomarkers
[70].
3.5. Metabolomic biomarkers
Metabolomics combines high-throughput analytical methodologies,
mainly MS or nuclear magnetic resonance (NMR) spectroscopy with
multivariate data analysis, to screen and compare low molecular mass
metabolites (< 1.5 kDa) in biological samples (Fig. 1). Investigating
the molecular composition of bile can provide important mechanistic
information regarding the pathological alterations of biliary epithelia,
and may also allow the identification of biomarkers released into bile
from nearby tumor cells. Some metabolite profiling studies of human
bile have been performed over the past few years to assess bile com-
position and identify relevant biomarkers for CCA [71] and other he-
patopancreatobiliary diseases [72]. Early works using NMR demon-
strated that the levels of phosphatidylcholine, bile acids and other
biliary lipids could distinguish CCA patients from individuals with be-
nign biliary diseases with high sensitivity and specificity [73]. More
recently, metabolic profiling of bile, also using NMR, established that
lower phosphatidylcholine, and elevated glycine- and taurine con-
jugated bile acids levels, were consistently found in CCA patients
compared with individuals with benign biliary diseases [74,75]. Al-
though these findings are encouraging there are concerns about the
reproducibility of many of these studies. This situation may be due in
part to the multiple analytical platforms used and the sample pre-
paration protocols, which need better standardized procedures [76].
Ideally, once biomarkers are identified in bile they could be tested in
more accessible and less invasive fluids, such as urine or serum. Al-
ternatively, metabolomics studies can also be performed directly on
serum. Remarkably, a recent report using a MS-based profiling platform
in serum from fasting patients identified an interesting metabolomic
signature based on four metabolites (21-deoxycortisol, bilirubin, ly-
soPC(14:0) and lysoPC(15:0)) that could be used for diagnosing CCA
with high accuracy. Moreover, this signature was able to differentiate
between intrahepatic and extrahepatic CCA [77]. The validation of this
promising set of metabolites in future prospective studies is eagerly
awaited.
4. Potential interest of CTCs in the search of CCA biomarkers
The interest of the liquid biopsy, especially that derived from blood,
is based on its capability to facilitate the identification of biomarkers
using a less invasive, less dangerous and less expensive but more in-
formative approach than solid biopsy. Liquid biopsy could permit the
analysis of DNA, miRNA, and EV, which may, as aforementioned, be
useful in the search of biomarkers for CCA. Nevertheless, we will focus
this section on the information provided on CTCs, which could help to
improve screening protocols and therapy, as well as supply valuable
data related to cancer chemoresistance and the risk of relapses [78].
Several strategies based on the identification of epithelial adhesion
molecules have been experimentally developed to identify CTCs in
different malignancies. However, CellSearch system by Veridex
(Janssen/Veridex; Raritan, NJ) is the first automated, standardized,
reproducible and FDA approved test for the use in advanced metastatic
breast [79], colon [80] and prostate cancer [81]. It is designed to
capture cells expressing cancer specific epithelial cell adhesion mole-
cules (EpCAM) using antibody-coated magnetic beads followed by po-
sitive identification of intact tumor cells using fluorescent nuclear
staining and cytokeratin detection using labeled antibodies. Biliary
cancer cells express EpCAM, which allows their identification using
CellSearch [82]. A preliminary pilot study including 13 patients with
iCCA showed that the presence of 2 or more CTCs, assessed by Cell-
Search in 7.5 ml of patients’ blood, at diagnosis (3/13) was not sig-
nificantly related to the staging of the diseases and patient survival after
a one-year follow-up [82]. Another study including a greater number of
patients with CCA (n = 88) showed that CTCs ≥2 (HR 8.2; 95% CI
1.8–57.5; p < 0.01) and CTCs ≥5 (HR 7.7; 95% CI 1.4–42.9;
p = 0.02) were both associated with shorter survival among patients
with metastasis, reaching no significance for non-metastatic CCA [83].
The study also showed that CTCs ≥2 (10.5; 95% CI 2.2–40.1;
p < 0.01) and CTCs ≥5 (HR 10.2; 95% CI 1.5–42.3; p = 0.02) were
both associated with shorter survival among patients with p/dCCA, but
only CTC≥5 was associated with shorter survival of patients with iCCA
(HR 4.2; 95% CI 1.1–14.1; p = 0.04) [83]. Results from another study
including 50 untreated patients with histologically or cytologically
confirmed advanced biliary cancer, either iCCA (58%), extrahepatic
CCA (20%) or gallbladder carcinoma (22%), at inoperable stage III or
IV with normal organ and marrow function, revealed that patients
without detectable CTCs (< 1 CTC per 7.5 mL blood) correlated with
higher overall survival as opposed to those with ≥1 CTC per 7.5 ml
blood (13.7 vs 9.4 months) [84]. However, these results were not sta-
tistically significant (p = 0.29), which might be due to the small sample
size and low power of the study. Further investigation in this field is
clearly needed.
5. Biomarkers in the prediction of CCA chemoresistance
The refractoriness of cancer to pharmacological treatment partly
depends on the expression of genes involved in different mechanisms of
chemoresistance (MOC), which were initially classified into five fa-
milies from MOC-1 to MOC-5 [85]. This classification, however, has
been recently extended to seven by including MOC-6 and MOC-7,
taking into consideration the updated advances in the field [86]. Fol-
lowing this classification (Fig. 3), we will comment on the potential
interest of MOC genes as biomarkers to predict chemoresistance in CCA
[87].
Impaired drug uptake (MOC-1a) can result in a lower response to
chemotherapy due to inaccessibility of the drug to target molecules,
similar to what occurs with sorafenib, whose uptake is mediated by
OCT1 that is dramatically downregulated both in HCC and CCA [88].
Some transporters involved in drug uptake could be used as biomarkers
to predict chemoresistance. Another example involves the equilibrative
nucleoside transporter 1 (ENT1), whose expression levels have been
suggested to predict of response to gemcitabine in CCA patients [89].
Several members of the superfamily of ATP-binding cassette (ABC)
proteins are involved in the efflux of a large variety of anticancer drugs
from tumor cells. The over-expression of these pumps is one of the
major causes of chemoresistance (MOC-1b). Elevated expression and
function of Multidrug Resistance Protein 1 (MDR1) has been associated
with lower sensitivity to 5-fluorouracil (5-FU) in CCA cells [90]. In vitro
studies using CCA cells have demonstrated the existence of the re-
lationship between elevated expression of Multidrug Resistance-Asso-
ciated Protein 1 (MRP1) and resistance to gemcitabine, and between
high levels of MRP3 overexpression and the chemoresistance to eto-
poside and anthracyclines [91]. Moreover, the overexpression of sev-
eral MRPs has been detected in clinical samples of CCA [37] and has
been associated with poor prognosis in CCA patients [92]. The con-
tribution of the Breast Cancer Resistance Protein (BCRP) to the che-
moresistance in CCA is not clear. However, it has been reported that 5-
FU resistant CCA cells exhibit high expression levels of this export pump
[90]. Furthermore, some data indicate that BCRP expression is in-
creased in CCA due to the activation mediated by the transcriptional
coactivator amplified in breast cancer 1 (AIB1) that has been found
overexpressed in CCA samples [93]. Thymosin β10, the main
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intracellular G-actin-sequestering protein involved in cell motility, has
been proposed as a predictive biomarker of response to 5-FU in CCA
because this protein is overexpressed in 5-FU resistant cells and its le-
vels reflected the expression of ABC proteins [90].
Changes in the expression of enzymes involved in drug metabolism,
either activating pro-drugs or inactivating active agents, can affect the
intracellular concentration of active compounds (MOC-2). The orotate
phosphoribosyl transferase (OPRT), responsible of the enzymatic
transformation of 5-FU to the active compound, has been proposed as
predictor of the outcome of CCA patients treated with 5-FU, because
significantly higher mRNA OPRT levels were found in 5-FU-CCA re-
sponder patients than in non-responders [94]. Glutathione S-trans-
ferase-pi (GSTP1) could be a biomarker of resistance to different drugs.
More precisely, high expression of this enzyme has been observed in
CCA specimens whereas the sensitivity to adriamycin, cisplatin, and
alkylating agents was higher when levels of this enzyme were reduced
[95].
Changes in the expression/functionality of molecular targets can
also account for anticancer drug resistance (MOC-3). As an example,
up-regulation of epidermal growth factor receptor (EGFR) has been
associated with chemoresistance to erlotinib [96] and cisplatin [97] in
CCA cells.
An enhanced ability of tumor cells to repair cytostatic drug-induced
alterations in DNA molecule contributes to poor response to che-
motherapy with drugs, such as cisplatin, whose mechanism of action is
based on damaging replicating DNA (MOC4). The excision repair cross-
complementing protein 1 (ERCC1) is an endonuclease that removes a
wide variety of bulky DNA adducts, such as those generated by cisplatin
and alkylating agents. Overexpression of ERCC1 has significant prog-
nostic value in advanced biliary tract carcinoma patients treated with
cisplatin [98]. The uracil-DNA glycosylase 1 (UNG1), which catalyzes
the hydrolysis of the N-glycosylic bond between uracil and sugar, has
been found up-regulated in 5-FU-resistant CCA cell lines [99], and in-
creased expression of the ribonucleotide reductase p53R2 has been
proposed to predict resistance to gemcitabine in CCA cell lines [100].
Changes in the balance between pro- and anti-apoptotic proteins
play a major role in the chemoresistance to many antitumor drugs
(MOC-5). Bcl-2 upregulation together with Bax downregulation have
been observed in 5-FU and cisplatin-CCA resistant cells [101]. BCL2
upregulation in clinical samples of CCA has been also reported [37].
Another example is the coupled appearance of upregulation of the
apoptotic inhibitor BIRC5 together with downregulation of the pro-
apoptotic factor TP73, which has been associated with development of
acquired 5-FU resistance in CCA cell lines [99]. BIRC5 upregulation was
also observed in paired samples of CCA and adjacent liver tissue [37].
Upregulation of a mutated isoform of p53 named Δ133p53 has been
correlated with poor survival outcome in CCA patients treated with 5-
FU [102], and the depletion of the transcription factor FoxO3, con-
sidered a tumor suppressor gene has been associated with resistance to
cisplatin [103].
The special characteristics of tumor microenvironment affect the
response to chemotherapy (MOC-6) and may be responsible for pro-
viding cancer cells with several pro-invasive functions [86]. Although
some data regarding MOC-6 in CCA have been recently published, the
actual importance of this group of MOC in CCA is still poorly under-
stood. Thus, in malignant cholangiocytes, the pro-inflammatory cyto-
kine leukemia inhibitory factor (LIF) has been found overexpressed.
This factor protects tumor cells from chemotherapy-induced apoptosis
via a STAT3- and MAPK-independent, PI3K/AKT-dependent Mcl-1 ac-
tivation. Another example is laminin-332, a protein of the extracellular
matrix that is overexpressed in hepatic tumors with high levels of CK19
and induces chemoresistance to doxorubicin and sorafenib [104].
The EMT process refers to the transformation of epithelial cells to a
mesenchymal phenotype, characterized by enhanced migratory beha-
vior, invasive ability, and resistance to apoptosis activation. Thus, EMT
has been associated to poorer response to chemotherapy (MOC-7) and
has been described in hepatic tumors, including CCA, where EMT has
been associated with changes in the expression of oncogenes and tumor
suppressor genes [105]. For instance, the overexpression of lipocalin-2
in CCA cells stimulates EMT progression and downregulates tumor
suppressor genes (NDRG1 and NDRG2), which results in enhanced re-
sistance to chemotherapy [106].
The identification of biomarkers associated with chemoresistance
can be useful to predict in an individualized manner what pharmaco-
logical regimes are likely to be less effective against a precise CCA
patient. Alterations in biomarkers in response to different therapies
have also been described and this knowledge can be used to select
strategies to overcome CCA chemoresistance. These questions have
been reviewed in a separate chapter of this special issue [107].
6. Conclusions and perspectives
There is an urgent need for new biomarkers for the diagnosis and
prognosis of CCA, especially in those populations at risk of developing
Fig. 3. Schematic representation of different me-
chanisms of chemoresistance (MOCs) in cholangio-
carcinoma cells.
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CCA, as well as early biomarkers of recurrence after surgery [2,24]. The
development of “omics” approaches offers a broad panel of new ways to
obtain large amounts of potentially useful information with respect to
the search of novel biomarkers. Although the field of liquid biopsy is in
its infancy, this has promising prospects, not only associated with CTC,
but also with miRNAs and EVs. In particular, miRNAs are gaining im-
portance in the field of CCA as potential biomarkers and targets for
therapy. These molecules could be especially helpful for solving diag-
nosis and prognosis challenges in CCA. Nevertheless, it should be
highlighted that there are many unsolved questions, including the op-
timal biofluid source of miRNA. Additionally, there are some aspects
that will need to be refined and optimized, such as normalization ap-
proaches and sample processing. Moreover, in order to standardize the
use of miRNAs in clinical practice, the best candidates should be vali-
dated in international collaborative studies that include different pa-
tient cohorts. In the future, a multidisciplinary approach, including
genetic, epigenetic and proteomic analyses, will help to provide a more
complete picture of the pathophysiological mechanisms involved in the
development of CCAs and the MOC involved in their high refractoriness
to available chemotherapy. This is a required step for the identification
of biomarkers with diagnostic and prognostic utility, but also specific
targeted therapies. Additionally, the search for new markers will need
to take into account the marked heterogeneity of these tumors. The
selection of a panel of biomarkers and appropriate algorithms will help
to unravel the complexity of this disease and, hopefully in the near
future, provide oncologists with more sensitive and specific tools to
achieve an accurate diagnosis and prognosis of CCA.
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